Patents Assigned to Intellikine LLC
-
Patent number: 11433065Abstract: Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.Type: GrantFiled: August 29, 2019Date of Patent: September 6, 2022Assignee: Intellikine LLCInventors: Pingda Ren, Yi Liu, Troy Edward Wilson, Liansheng Li, Katrina Chan, Christian Rommel
-
Patent number: 10172858Abstract: The present invention provides for methods and pharmaceutical compositions for treating proliferative disorders. In one aspect, the method comprises administration of two cell-cycle suppressors having a synergistic effect. In another aspect, two cell-cycle suppressors having a synergistic effect are provided in a pharmaceutical composition.Type: GrantFiled: April 7, 2016Date of Patent: January 8, 2019Assignee: INTELLIKINE LLCInventors: Yi Liu, Pingda Ren, Katayoun Jessen, Xin Guo, Christian Rommel
-
Patent number: 9828378Abstract: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.Type: GrantFiled: July 7, 2015Date of Patent: November 28, 2017Assignee: Intellikine LLCInventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson
-
Patent number: 9822131Abstract: Chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with P13 kinase activity are described herein.Type: GrantFiled: March 3, 2016Date of Patent: November 21, 2017Assignee: Intellikine LLCInventors: Pingda Ren, Yi Liu, Troy Edward Wilson, Katrina Chan, Christian Rommel, Liansheng Li
-
Patent number: 9790228Abstract: Provided herein are compounds of formula (I-A), (I-B), (I-C), or (I-D), pharmaceutical compositions comprising the compounds, and methods of use thereof. The compounds provided herein modulate kinase activity, including PI3 kinase activity, and are useful for treating diseases and conditions associated with kinase activity, including diseases and conditions associated with PI3 kinase activity.Type: GrantFiled: February 22, 2016Date of Patent: October 17, 2017Assignee: Intellikine LLCInventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson
-
Patent number: 9682141Abstract: The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or a receptor tyrosine kinase (RTK) in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase ? and/or an RTK in a subject. In yet another aspect, a method of inhibiting phosphorylation of Akt (S473) in a cell is set forth.Type: GrantFiled: November 12, 2012Date of Patent: June 20, 2017Assignee: Intellikine LLCInventors: Katayoun Jessen, Xin Guo, Pingda Ren, Christian Rommel, Yi Liu
-
Patent number: 9669032Abstract: The present invention provides for methods and pharmaceutical compositions comprising inhibitors of mTorC1 and/or mTorC2. In some aspects, the invention provides for treatment regimens resulting in enhanced treatment efficacy and better tolerability.Type: GrantFiled: October 15, 2015Date of Patent: June 6, 2017Assignee: Intellikine LLCInventors: Yi Liu, Lynne Bui, Michael Martin, Troy Edward Wilson, Christian Rommel
-
Patent number: 9655892Abstract: Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.Type: GrantFiled: November 11, 2015Date of Patent: May 23, 2017Assignee: Intellikine LLCInventors: Pingda Ren, Yi Liu, Troy Edward Wilson, Liansheng Li, Katrina Chan, Christian Rommel
-
Patent number: 9637492Abstract: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating lipid kinases such PI3 kinases, tryosine kinases and protein kinases such as mTOR. Also provided in the present invention are methods of using these compositions to modulate these kinases especially for therapeutic applications.Type: GrantFiled: February 11, 2015Date of Patent: May 2, 2017Assignee: Intellikine LLCInventors: Pingda Ren, Yi Liu, Troy Edward Wilson, Liansheng Li, Katrina Chan
-
Patent number: 9522146Abstract: Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.Type: GrantFiled: October 15, 2015Date of Patent: December 20, 2016Assignee: Intellikine LLCInventors: Pingda Ren, Yi Liu, Troy Edward Wilson, Liansheng Li, Katrina Chan, Christian Rommel
-
Patent number: 9403820Abstract: Polymorphs of chemical compounds that modulate kinase activity, including PI3K activity, and chemical compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3K activity, are described herein.Type: GrantFiled: November 12, 2012Date of Patent: August 2, 2016Assignees: Intellikine LLC, Sigma-Aldrich Company LimitedInventors: Pingda Ren, Michael Martin, Christopher Peter Worrall, Susanna del Rio Gancedo
-
Patent number: 9359349Abstract: The present invention provides compounds of Formula I that modulate PI3 kinase activity and methods of treatment of diseases and conditions associated with PI3 kinase activity.Type: GrantFiled: September 19, 2014Date of Patent: June 7, 2016Assignee: INTELLIKINE LLCInventors: Pingda Ren, Yi Liu, Troy Edward Wilson
-
Patent number: 9359352Abstract: The present invention provides substituted benzimidazole compounds of Formula I: wherein the variables R1, R2, W1, W2, W3, W4, W5, W6, Wa, Wb, Wc and Wd are defined herein. The compounds are useful as phosphoinositide 3-kinase (PI3 kinase) inhibitors.Type: GrantFiled: July 16, 2015Date of Patent: June 7, 2016Assignee: Intellikine LLCInventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson, Simon Fraser Campbell
-
Patent number: 9345706Abstract: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.Type: GrantFiled: June 1, 2015Date of Patent: May 24, 2016Assignee: Intellikine, LLCInventors: Pingda Ren, Yi Liu, Troy Edward Wilson, Liansheng Li, Katrina Chan
-
Patent number: 9315505Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the isoquinolone entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.Type: GrantFiled: June 11, 2014Date of Patent: April 19, 2016Assignee: Intellikine LLCInventors: Pingda Ren, Yi Liu, Liansheng Li, Troy Edward Wilson
-
Patent number: 9296742Abstract: Provided herein are compounds of formula (I-A), (I-B), (I-C), or (I-D), pharmaceutical compositions comprising the compounds, and methods of use thereof. The compounds provided herein modulate kinase activity, including PI3 kinase activity, and are useful for treating diseases and conditions associated with kinase activity, including diseases and conditions associated with PI3 kinase activity.Type: GrantFiled: March 21, 2014Date of Patent: March 29, 2016Assignee: Intellikine LLCInventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson
-
Patent number: 9295673Abstract: The present invention provides for a method for treating a disease condition associated with PI3-kinase ? and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase ? and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.Type: GrantFiled: February 23, 2012Date of Patent: March 29, 2016Assignee: Intellikine LLCInventors: Pingda Ren, Yi Liu, Katayoun Jessen, Xin Guo, Christian Rommel, Troy Edward Wilson
-
Patent number: 9216982Abstract: Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.Type: GrantFiled: June 5, 2014Date of Patent: December 22, 2015Assignee: Intellikine LLCInventors: Pingda Ren, Yi Liu, Troy Edward Wilson, Liansheng Li, Katrina Chan, Christian Rommel
-
Patent number: 9206182Abstract: Substituted isoquinolin-1(2H)-one compounds that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.Type: GrantFiled: August 20, 2013Date of Patent: December 8, 2015Assignee: Intellikine LLCInventors: Pingda Ren, Yi Liu, Troy Edward Wilson, Liansheng Li, Katrina Chan, Christian Rommel
-
Patent number: 9174994Abstract: The present invention provides for methods and pharmaceutical compositions comprising inhibitors of mTorC1 and/or mTorC2. In some aspects, the invention provides for treatment regimens resulting in enhanced treatment efficacy and better tolerability.Type: GrantFiled: November 21, 2012Date of Patent: November 3, 2015Assignee: Intellikine, LLCInventors: Yi Liu, Lynne Bui, Michael Martin, Troy Edward Wilson, Christian Rommel